GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Sale Of Property, Plant, Equipment

ENTA (Enanta Pharmaceuticals) Sale Of Property, Plant, Equipment : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Sale Of Property, Plant, Equipment?

Enanta Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Enanta Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment. Enanta Pharmaceuticals's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2024 ), Enanta Pharmaceuticals gained the same money from selling property, plant, and equipment in Sep. 2024 ($0.00 Mil).

Enanta Pharmaceuticals Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Enanta Pharmaceuticals's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Sale Of Property, Plant, Equipment Chart

Enanta Pharmaceuticals Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Sale Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enanta Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enanta Pharmaceuticals Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
MCRB SCPH RENB AEON INZY TCRX SELB IVVD GRTS DNTH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
4 Kingsbury Avenue, Watertown, MA, USA, 02472
Website
https://www.enanta.com
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Scott T. Rottinghaus officer: Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Terry Vance director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or officer: Chief Scientific Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly director, officer: President and CEO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett officer: Treasurer and CFO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta director AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901